– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in…
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage…
Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ETLITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos…
BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an…
– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training…
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of…
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American…
Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024…
Financial filings are expected after the market closes on May 27, and a management conference call will follow the next…